Page last updated: 2024-11-12

cyperotundone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyperotundone: from Cyperus rotundus L.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
CyperusgenusA plant genus of the family CYPERACEAE. SESQUITERPENES are found in some of the species.[MeSH]CyperaceaeThe sedge plant family of the order Cyperales, subclass Commelinidae, class Liliopsida (monocotyledons)[MeSH]
Cyperus rotundusspecies[no description available]CyperaceaeThe sedge plant family of the order Cyperales, subclass Commelinidae, class Liliopsida (monocotyledons)[MeSH]

Cross-References

ID SourceID
PubMed CID12308614
CHEBI ID81137
MeSH IDM0537143

Synonyms (7)

Synonym
C17501
cyperotundone
CHEBI:81137
4,10,11,11-tetramethyltricyclo[5.3.1.0^{1,5}]undec-4-en-3-one
Q27155094
FT-0775620
4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-en-3-one

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Overall, our findings showed that CYT in combination with ADR has potent anti-breast cancer cell activity both in vivo and in vitro, suggesting CYT as the main drug used to improve chemosensitivity."( Cyperotundone combined with adriamycin induces apoptosis in MCF-7 and MCF-7/ADR cancer cells by ROS generation and NRF2/ARE signaling pathway.
Liu, X; Liu, Z; Shao, W; Song, X; Wang, F; Wang, X; Yu, Z, 2023
)
2.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sesquiterpenoidAny terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.36 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]